No abstract

No abstract

SummaryBackground: CHOP is currently considered the gold standard of treatment for intermediate grade lymphomas. We designed a new regimen known as 'ATT' (alternating triple therapy) which uses three non-cross resistant combinations in alternating sequence for nine cycles.Materials and methods: This is a phase II clinical trial with comparison to CHOP/CM ED historical controls using prognostic factors. The tumor score system was used to evaluate the results of this trial. Two hundred sixty-eight eligible patients who had one or more of the following adverse features: bulky disease, elevated LDH or > 1 extranodal site were analyzed. Outcome measures consist of survival and failure free survival.Results: At a median follow-up of 32 months, there was no statistically significant difference in survival for those with favorable prognostic factors (tumor score ^ 2). However, there was a statistically significant difference in favor of ATT for those with unfavorable tumor scores. When we examined the failure-free survival of those with unfavorable tumor scores,

No abstract

No abstract